TNFRSF1B and cancer: Although immunosuppressive cells do not have a monopoly on TNFR2 expression in the steady-state, a large number of studies suggest that TNFR2+ Tregs with high suppressive capacity are strongly represented in the TME of cancer patients and sometimes the peripheral blood, comparable to findings in mouse models (Chen et al., 2008).